CCAP vs. LU, UPST, PWP, CIFR, SII, IREN, ML, CORZ, HUT, and PGY
Should you be buying Crescent Capital BDC stock or one of its competitors? The main competitors of Crescent Capital BDC include Lufax (LU), Upstart (UPST), Perella Weinberg Partners (PWP), Cipher Mining (CIFR), Sprott (SII), Iris Energy (IREN), MoneyLion (ML), Core Scientific (CORZ), Hut 8 (HUT), and Pagaya Technologies (PGY). These companies are all part of the "nondepository credit institutions" industry.
Lufax (NYSE:LU) and Crescent Capital BDC (NASDAQ:CCAP) are both finance companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.
69.1% of Lufax shares are owned by institutional investors. Comparatively, 49.5% of Crescent Capital BDC shares are owned by institutional investors. 1.0% of Crescent Capital BDC shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Lufax currently has a consensus target price of $6.40, indicating a potential upside of 42.86%. Crescent Capital BDC has a consensus target price of $18.75, indicating a potential upside of 3.36%. Given Crescent Capital BDC's higher possible upside, equities analysts plainly believe Lufax is more favorable than Crescent Capital BDC.
Crescent Capital BDC has a net margin of 53.32% compared to Crescent Capital BDC's net margin of -2.17%. Lufax's return on equity of 11.99% beat Crescent Capital BDC's return on equity.
In the previous week, Crescent Capital BDC had 5 more articles in the media than Lufax. MarketBeat recorded 8 mentions for Crescent Capital BDC and 3 mentions for Lufax. Lufax's average media sentiment score of 0.85 beat Crescent Capital BDC's score of 0.54 indicating that Crescent Capital BDC is being referred to more favorably in the news media.
Lufax has higher revenue and earnings than Crescent Capital BDC. Lufax is trading at a lower price-to-earnings ratio than Crescent Capital BDC, indicating that it is currently the more affordable of the two stocks.
Crescent Capital BDC received 7 more outperform votes than Lufax when rated by MarketBeat users. Likewise, 55.56% of users gave Crescent Capital BDC an outperform vote while only 43.40% of users gave Lufax an outperform vote.
Lufax has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Crescent Capital BDC has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500.
Lufax pays an annual dividend of $0.25 per share and has a dividend yield of 5.6%. Crescent Capital BDC pays an annual dividend of $1.64 per share and has a dividend yield of 9.0%. Lufax pays out -178.6% of its earnings in the form of a dividend. Crescent Capital BDC pays out 58.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
Summary
Crescent Capital BDC beats Lufax on 14 of the 20 factors compared between the two stocks.
Get Crescent Capital BDC News Delivered to You Automatically
Sign up to receive the latest news and ratings for CCAP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CCAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Crescent Capital BDC Competitors List
Related Companies and Tools
